Dogwood Therapeutics says it has regained Nasdaq stockholders' equity compliance

How the company got back into compliance

Dogwood Therapeutics, Inc. said on April 3, 2025 that it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement under Listing Rule 5550(b)(1), according to a press release filed with the SEC. Nasdaq sent a letter on November 15, 2024 saying the company's stockholders' equity had fallen below the $2.5 million minimum. Dogwood submitted a compliance plan on December 27, 2024. On February 2, 2025, Nasdaq gave it until May 14, 2025 to regain compliance. Stockholders' equity is a company's assets minus its liabilities. Two transactions brought equity above the minimum, the company said. On March 12, 2025, it signed a Debt Exchange and Cancellation Agreement with Conjoint, Inc. It issued Series A-1 Non-Voting Convertible Preferred Stock to Conjoint in exchange for the cancellation of approximately $19.9 million the company owed. The same day, it agreed to sell common stock to certain institutional investors for gross proceeds of approximately $4.8 million. The release says the company believes its equity is now above the minimum. It does not include a Nasdaq confirmation, and it does not state the equity figure itself. The compliance therefore rests on a debt exchange and a stock sale, not on operating results.

Cash, debt and the share count

Chairman and CEO Greg Duncan said the company has a strong cash position of $17.5 million as of the end of Q1, with no debt. That is the company's own statement. The release gives no balance sheet and no cash burn figure, so the $17.5 million cannot be checked against a cash-flow statement in it. The debt exchange turned about $19.9 million of owed money into convertible preferred stock. That removes the debt from the balance sheet but gives the holder a security that can convert into common shares. The release does not say how many common shares the preferred could become. As of March 31, 2025, Dogwood had 1,911,128 shares of common stock issued and outstanding.

The lead drug and its trial record

Dogwood describes itself as a pre-revenue, development-stage biopharmaceutical company. Its lead candidate, Halneuron, is a sodium channel modulator with highly purified tetrodotoxin as the active ingredient. The company says it is in late-stage clinical development for chemotherapy-induced neuropathic pain, or CINP, a condition with no FDA-approved treatment. Its market research puts the CINP drug market at about $1.5 billion a year and the larger cancer-related pain market at about $5 billion in yearly sales. The previous Phase 2 study in cancer-related pain enrolled 165 patients at 19 sites. 77 were randomized to Halneuron and 88 to placebo. The company says 51% of Halneuron patients had at least a 30% reduction in pain, against 35% on placebo, and it calls the benefit statistical and clinically relevant. The average pain response among responders lasted 57.7 days on Halneuron, against 10.5 days on placebo. The annual report also says all patients in the Halneuron group reported at least one treatment-emergent adverse event that the company considered related to the study drug. A study of 165 patients is small, and the benefit claims come from the company's own trial. The release says interim data from the ongoing Halneuron Phase 2 CINP study are expected in Q4 2025.

The antiviral programs

The other pillar is an antiviral program built on two fixed-dose combinations, IMC-1 and IMC-2, which pair anti-herpes antivirals with celecoxib. The company says IMC-1 is poised to progress into Phase 3 for fibromyalgia and is the focus of external partnership activity. IMC-2 is described as having reduced fatigue associated with Long-COVID in active control and placebo-controlled trials. The company says it reached an agreement with the FDA on using a reduction in fatigue as the primary endpoint for future Long-COVID research, and that it is planning to advance IMC-2 into Phase 2b research. Those are the company's plans, and the release reports no new trial data for IMC-2.

Report an error

Companies in this story

DWTXDogwood Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk